Patents by Inventor Hergen Spits

Hergen Spits has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MEANS AND METHODS FOR COUNTERACTING MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISORDERS
    Publication number: 20230242667
    Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.
    Type: Application
    Filed: February 22, 2023
    Publication date: August 3, 2023
    Inventors: Hergen SPITS, Tim BEAUMONT, Marijn Aletta GILLISSEN, Adrianus Quirinus BAKKER, Mette Deborah HAZENBERG, Martijn KEDDE
  • AML ANTIGENS AND USES THEREOF
    Publication number: 20230235018
    Abstract: The present invention provides novel compounds comprising an antigen of AML cells, and uses thereof.
    Type: Application
    Filed: October 27, 2022
    Publication date: July 27, 2023
    Inventors: Hergen SPITS, Marijn Aletta GILLISSEN, Martijn KEDDE, Mette Deborah HAZENBERG, Paula Maria Wilhelmina VAN HELDEN, Wouter POS
  • Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
    Patent number: 11629200
    Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: April 18, 2023
    Assignee: KLING BIOTHERAPEUTICS B.V.
    Inventors: Hergen Spits, Tim Beaumont, Marijn Aletta Gillissen, Adrianus Quirinus Bakker, Mette Deborah Hazenberg, Martijn Kedde
  • AML antigens and uses thereof
    Patent number: 11524989
    Abstract: The present invention provides novel compounds comprising an antigen of AML cells, and uses thereof.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: December 13, 2022
    Assignee: KLING BIOTHERAPEUTICS B.V.
    Inventors: Hergen Spits, Marijn Aletta Gillissen, Martijn Kedde, Mette Deborah Hazenberg, Paula Maria Wilhelmina van Helden, Wouter Pos
  • Therapeutic Anti-CD9 Antibody
    Publication number: 20220064323
    Abstract: The present invention provides novel binding compounds and therapeutic applications thereof.
    Type: Application
    Filed: September 16, 2021
    Publication date: March 3, 2022
    Inventors: Hergen SPITS, Paula Maria Wilhelmina VAN HELDEN, Remko SCHOTTE, Wouter POS, Christien FATMAWATI, Danïel Michiel GO, Koen WAGNER, Julien Christian VILLAUDY
  • Therapeutic anti-CD9 antibody
    Patent number: 11136407
    Abstract: The present invention provides novel binding compounds and therapeutic applications thereof.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: October 5, 2021
    Assignee: AIMM Therapeutics B.V.
    Inventors: Hergen Spits, Paula Maria Wilhelmina Van Helden, Remko Schotte, Wouter Pos, Christien Fatmawati, Danïel Michiel Go, Koen Wagner, Julien Christian Villaudy
  • RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM
    Publication number: 20200325213
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: June 29, 2020
    Publication date: October 15, 2020
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • Means and methods for influencing the stability of cells
    Patent number: 10774308
    Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: September 15, 2020
    Assignees: ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM, AIMM THERAPEUTICS B.V.
    Inventor: Hergen Spits
  • RSV-specific binding molecules and means for producing them
    Patent number: 10730931
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: August 4, 2020
    Assignee: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • MEANS AND METHODS FOR COUNTERACTING MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISORDERS
    Publication number: 20200239593
    Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.
    Type: Application
    Filed: January 3, 2020
    Publication date: July 30, 2020
    Inventors: Hergen SPITS, Tim BEAUMONT, Marijn Aletta GILLISSEN, Adrianus Quirinus BAKKER, Mette Deborah HAZENBERG, Martijn KEDDE
  • Means and methods for determining T cell recognition
    Patent number: 10690658
    Abstract: The invention provides improved screening methods for testing T cell recognition of T cell epitopes.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: June 23, 2020
    Assignees: AIMM THERAPEUTICS B.V., STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
    Inventors: Carsten Linnemann, Laura Bies, Marit Martha van Buuren, Antonius Nicolaas Maria Schumacher, Hergen Spits, Remko Schotte
  • EX VIVO ANTIBODY PRODUCTION
    Publication number: 20200149007
    Abstract: The present invention provides means and methods for producing improved ex vivo B cell cultures with a short doubling time.
    Type: Application
    Filed: September 19, 2019
    Publication date: May 14, 2020
    Inventors: PAULA MARIA WILHELMINA VAN HELDEN, Mark Jeroen KWAKKENBOS, Hergen Spits, Tim Beaumont
  • Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
    Patent number: 10556963
    Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: February 11, 2020
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Hergen Spits, Tim Beaumont, Marijn Aletta Gillissen, Adrianus Quirinus Bakker, Mette Deborah Hazenberg, Martijn Kedde
  • Means and methods for producing high affinity antibodies
    Patent number: 10344076
    Abstract: The invention provides means and methods for modulating the occurrence of somatic hypermutations in antibody producing plasmablast-like B-cells.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: July 9, 2019
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Hergen Spits, Adrianus Quirinus Bakker
  • Means and methods for influencing the stability of antibody producing cells
    Patent number: 10273454
    Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: April 30, 2019
    Assignee: ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
    Inventors: Hergen Spits, Ferenc A. Scheeren, Tim Beaumont, Sean A. Diehl
  • Therapeutic Anti-CD9 Antibody
    Publication number: 20190023803
    Abstract: The present invention provides novel binding compounds and therapeutic applications thereof.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 24, 2019
    Applicant: AIMM Therapeutics B.V.
    Inventors: Hergen SPITS, Paula Maria Wilhelmina VAN HELDEN, Remko SCHOTTE, Wouter POS, Christien FATMAWATI, Danïel Michiel GO, Koen WAGNER, Julien Christian VILLAUDY
  • MEANS AND METHODS FOR INFLUENCING THE STABILITY OF CELLS
    Publication number: 20180371410
    Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.
    Type: Application
    Filed: August 28, 2018
    Publication date: December 27, 2018
    Inventor: Hergen SPITS
  • RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM
    Publication number: 20180327484
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: July 23, 2018
    Publication date: November 15, 2018
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • Means and methods for influencing the stability of cells
    Patent number: 10077427
    Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: September 18, 2018
    Assignees: ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM, AIMM THERAPEUTICS B.V.
    Inventor: Hergen Spits
  • RSV-specific binding molecules and means for producing them
    Patent number: 10059757
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: August 28, 2018
    Assignee: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda